Dublin-based Malin is tapping more of Andrew von Eschenbach’s time.
The former FDA chief has signed on as chief medical adviser to the biotech investor, after a stint in the somewhat less formal position of advisory partner.
Malin, which recently saw Kelly Martin step down as chief in favor of Adrian Howd, is looking for more input from von Eschenbach for the oncology companies in its portfolio — like Poseida and Immunocore, which is now in the midst of a major new raise.
Martin has been upping his time at the companies Malin has invested in, such as the troubled UNC spinout Novan.
Von Eschenbach was head of the National Cancer Institute for the four years prior to taking the reins at the FDA from 2006 to 2009 under President George W. Bush. He’s now also a senior fellow at the Milken Institute and president of Samaritan Health Initiatives.
Von Eschenbach commented:
I am thrilled for the opportunity to collaborate more closely with the Malin team and its investee companies. Now is a great time for me to join in a formal role as the portfolio continues to mature towards clinical and regulatory milestones. Malin’s investee companies have already made tremendous strides and I look forward to playing a greater role in their journey.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,500+ biopharma pros who read Endpoints News by email every day.Free Subscription